Edge Pharma is preparing an ANDA submission for FDA approval of methacholine chloride

Published: September 10, 2019

Edge Pharma, one of the leaders in 503B pharmaceutical outsourcing, is excited to announce that it is preparing the required ANDA submissions to the FDA for approval of a generic methacholine chloride. Methacholine chloride is typically used during a challenge test as a means to diagnose bronchial hyperresponsiveness. According to Edge’s CEO Bill Chatoff,

If you don't have an account, please complete this registration form to read our blog.

If you have an existing client account you can login to view this post.